S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:AXGN

AxoGen (AXGN) Stock Forecast, Price & News

$8.97
+0.25 (+2.87%)
(As of 06/6/2023 ET)
Compare
Today's Range
$8.56
$9.03
50-Day Range
$8.50
$10.38
52-Week Range
$7.20
$13.66
Volume
125,435 shs
Average Volume
211,649 shs
Market Capitalization
$383.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

AxoGen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
89.5% Upside
$17.00 Price Target
Short Interest
Healthy
1.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of AxoGen in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$365,646 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.64) to ($0.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

325th out of 984 stocks

Electromedical Equipment Industry

7th out of 22 stocks


AXGN stock logo

About AxoGen (NASDAQ:AXGN) Stock

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AXGN Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
AxoGen Q1 2023 Earnings Preview
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
AxoGen (AXGN) to Release Quarterly Earnings on Tuesday
AxoGen (NASDAQ:AXGN) Stock Rating Upgraded by StockNews.com
Short Interest in AxoGen, Inc. (NASDAQ:AXGN) Expands By 19.3%
AxoGen (NASDAQ:AXGN) Rating Lowered to Hold at StockNews.com
AxoGen Full Year 2022 Earnings: EPS Beats Expectations
See More Headlines

AXGN Price History

AXGN Company Calendar

Last Earnings
3/14/2023
Today
6/06/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXGN
Employees
428
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+89.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-28,950,000.00
Pretax Margin
-17.01%

Debt

Sales & Book Value

Annual Sales
$138.58 million
Book Value
$2.39 per share

Miscellaneous

Free Float
39,586,000
Market Cap
$383.92 million
Optionable
Optionable
Beta
0.61

Key Executives

  • Karen L. ZaderejKaren L. Zaderej
    Chairman, President & Chief Executive Officer
  • Mike Donovan
    Vice President-Operations
  • Peter J. Mariani
    Chief Financial Officer & Executive Vice President
  • Erick Wayne DeVinney
    Vice President-Clinical & Translational Sciences
  • Ivica Ducic
    Medical Director













AXGN Stock - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings
or view top-rated stocks.

What is AxoGen's stock price forecast for 2023?

4 brokerages have issued 1 year target prices for AxoGen's stock. Their AXGN share price forecasts range from $15.00 to $20.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 89.5% from the stock's current price.
View analysts price targets for AXGN
or view top-rated stocks among Wall Street analysts.

How have AXGN shares performed in 2023?

AxoGen's stock was trading at $9.98 at the beginning of the year. Since then, AXGN stock has decreased by 10.1% and is now trading at $8.97.
View the best growth stocks for 2023 here
.

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our AXGN earnings forecast
.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) released its earnings results on Tuesday, March, 14th. The medical equipment provider reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.06. The medical equipment provider had revenue of $36.20 million for the quarter, compared to the consensus estimate of $36.10 million. AxoGen had a negative trailing twelve-month return on equity of 15.23% and a negative net margin of 17.01%.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $154.00 million-$159.00 million, compared to the consensus revenue estimate of $156.67 million.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (8.54%), BlackRock Inc. (7.45%), First Light Asset Management LLC (4.53%), Bank of America Corp DE (4.17%), William Blair Investment Management LLC (3.73%) and Perceptive Advisors LLC (3.29%). Insiders that own company stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends
.

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $8.97.

How much money does AxoGen make?

AxoGen (NASDAQ:AXGN) has a market capitalization of $383.92 million and generates $138.58 million in revenue each year. The medical equipment provider earns $-28,950,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

How many employees does AxoGen have?

The company employs 428 workers across the globe.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801.

This page (NASDAQ:AXGN) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -